Quantitation of TIMP-1 in Plasma of Healthy Blood Donors and Patients with Advanced Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Jul 17

PMID 10408859

Citations 34

Authors

M N Holten-Andersen

G Murphy

H J Nielsen

A N Pedersen

I J Christensen

G Hoyer-Hansen

N Brunner

R W Stephens

Affiliations

Soon will be listed here.

Abstract

A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2+/-13.1 microg I(-1)) correlated with TIMP-1 measured in EDTA plasma (mean 73.5+/-14.2 microg I(-1)) from the same individuals in a set of 100 healthy blood donors (Spearman's rho = 0.62, P< 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes' stage D colorectal cancer was 240+/-145 microg I(-1) and a Mann-Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292+/-331 microg I(-1)). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.

Citing Articles

TIMP1 Indicates Poor Prognosis of Renal Cell Carcinoma and Accelerates Tumorigenesis EMT Signaling Pathway.

Shou Y, Liu Y, Xu J, Liu J, Xu T, Tong J Front Genet. 2022; 13:648134.

PMID: 35281807 PMC: 8914045. DOI: 10.3389/fgene.2022.648134.

Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.

Qin L, Wang Y, Yang N, Zhang Y, Zhao T, Wu Y PeerJ. 2021; 9:e10859.

PMID: 33628641 PMC: 7894117. DOI: 10.7717/peerj.10859.

Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.

Zhang Y, Qin L, Ma X, Wang Y, Wu Y, Jiang J Dis Markers. 2020; 2020:8831466.

PMID: 33005257 PMC: 7509560. DOI: 10.1155/2020/8831466.

Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.

Aaberg-Jessen C, Fogh L, Sorensen M, Halle B, Brunner N, Kristensen B Pathol Oncol Res. 2017; 25(1):59-69.

PMID: 28963609 DOI: 10.1007/s12253-017-0312-5.

Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.

Aaberg-Jessen C, Halle B, Jensen S, Muller S, Romer U, Pedersen C J Neurooncol. 2016; 130(3):439-448.

PMID: 27619981 PMC: 5118392. DOI: 10.1007/s11060-016-2252-4.

References

Matrisian L . The matrix-degrading metalloproteinases. Bioessays. 1992; 14(7):455-63. DOI: 10.1002/bies.950140705. View

Khokha R, Zimmer M, Graham C, Lala P, Waterhouse P . Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst. 1992; 84(13):1017-22. DOI: 10.1093/jnci/84.13.1017. View

Moutsiakis D, Mancuso P, Krutzsch H, Zucker S . Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res. 1992; 28(3):213-30. DOI: 10.3109/03008209209015038. View

Kleiner Jr D, Tuuttila A, Tryggvason K, Stetler-Stevenson W . Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry. 1993; 32(6):1583-92. DOI: 10.1021/bi00057a024. View

Birkedal-Hansen H, Moore W, Bodden M, Windsor L, DeCarlo A, Engler J . Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993; 4(2):197-250. DOI: 10.1177/10454411930040020401. View

Stetler-Stevenson W, Liotta L, Kleiner Jr D . Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993; 7(15):1434-41. DOI: 10.1096/fasebj.7.15.8262328. View

Fujimoto N, Zhang J, Iwata K, Shinya T, Okada Y, Hayakawa T . A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies. Clin Chim Acta. 1993; 220(1):31-45. DOI: 10.1016/0009-8981(93)90004-n. View

Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J . Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer. 1994; 70(3):506-12. PMC: 2033376. DOI: 10.1038/bjc.1994.336. View

Khokha R, Waterhouse P . The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol. 1993; 18(2):123-7. DOI: 10.1007/BF01050418. View

10.

Thorgeirsson U, Lindsay C, Cottam D, Gomez D . Tumor invasion, proteolysis, and angiogenesis. J Neurooncol. 1993; 18(2):89-103. DOI: 10.1007/BF01050415. View

11.

Nuovo G, MacConnell P, Simsir A, Valea F, French D . Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 1995; 55(2):267-75. View

12.

Yoshiji H, Gomez D, Thorgeirsson U . Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer. 1996; 69(2):131-4. DOI: 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C. View

13.

Zucker S, Lysik R, DiMassimo B, Zarrabi H, Moll U, Grimson R . Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer. 1995; 76(4):700-8. DOI: 10.1002/1097-0142(19950815)76:4<700::aid-cncr2820760426>3.0.co;2-5. View

14.

De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A . 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol. 1996; 15(2):102-9. DOI: 10.1097/00004347-199604000-00003. View

15.

Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M . Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 1996; 56(14):3196-8. View

16.

Stetler-Stevenson W, Hewitt R, Corcoran M . Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996; 7(3):147-54. DOI: 10.1006/scbi.1996.0020. View

17.

MacDougall J, Matrisian L . Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 1995; 14(4):351-62. DOI: 10.1007/BF00690603. View

18.

Deng G, Curriden S, Wang S, Rosenberg S, Loskutoff D . Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J Cell Biol. 1996; 134(6):1563-71. PMC: 2120994. DOI: 10.1083/jcb.134.6.1563. View

19.

Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening S . What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?. Clin Chim Acta. 1996; 254(1):97-100. DOI: 10.1016/0009-8981(96)06367-x. View

20.

Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening S . Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem. 1996; 42(12):2043-5. View